DFE Pharma will have a change in ownership. Fonterra and CVC Capital Partners’ Strategic Opportunities platform have agreed on a transaction for Fonterra’s 50% share in DFE Pharma. CVC is a leading private equity and investment advisory firm with approximately US$83 billion of assets under management and a global network of 24 offices. CVC’s Strategic Opportunities platform invests in high-quality businesses with longer growth horizons and the investment in DFE Pharma fits perfectly within this strategy, especially with the joint ownership with FrieslandCampina.
Bas van Driel, CEO of DFE Pharma said: “We are excited to be partnering with CVC and look forward to working with them to continue to deliver the best possible solutions to our customers. CVC’s international network, experience and track record in pharma, as well as support capabilities will be essential in expanding the breadth of our business. DFE Pharma’s other parent company, FrieslandCampina, will maintain its 50% share and its management control in the company, and will continue to support DFE Pharma's growth ambitions. The combination of FrieslandCampina and CVC as shareholders will provide DFE Pharma extra opportunities to excel.”
The change in ownership of DFE Pharma will not affect our supply of excipients. Fonterra will stay committed to the business through a long-term supply agreement.